Table 1 Patient characteristics.

Variable	Category	Number of cases	Primary disease		p-value
Variable	Category	Number of cases	Osteoporosis	Malignancy	p-value
Age	(years)	77 ± 10	80 ± 9	72 ± 10	< 0.001
Sex	Man	207	53	154	< 0.001
Sex	Woman	577	420	157
MRONJ site	Uppper jaw	214	121	93	0.184
MRONJ site	Lower jaw	570	352	218
MRONJ stage	1	272	153	119	0.129
	2	364	222	142
	3	148	98	50
Sort of ARA	BP	468	351	117	< 0.001
	DMB	221	80	141
	BP→DMB	95	42	53
Drug holiday	(−)	420	259	161	0.034
	(+)	331	188	143
	Unknown	33	26	7
Duration of ARA administration	(months)	47 ± 36	54 ± 40	38 ± 29	< 0.001
Steroid use	(−)	586	358	228	0.557
Steroid use	(+)	198	115	83
Diabetes	(−)	645	395	250	0.263
Diabetes	(+)	139	78	61
Leukocytes	(/µl)	7066 ± 3252	7246 ± 3082	6817 ± 3464	0.100
Lymphocytes	(/µl)	1707 ± 1496	1717 ± 1088	1694 ± 1929	0.856
Serum creatinine	(mg/dl)	0.92 ± 0.66	0.89 ± 0.61	0.96 ± 0.73	0.203
Serum albumin	(g/dl)	3.7 ± 0.51	3.71 ± 0.52	3.7 ± 0.5	0.820
Treatment method	Conservative	266	127	139	< 0.001
	Surgical	420	309	111
	Conservative →Surgical	98	37	61
Total		784	473	311

MRONJ, medication-related osteonecrosis of the jaw; ARA, antiresorptive agent; BP, bisphosphonate; DMB, denosumab.

Quick links

Search